[Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].

The purpose of this study was to analyze the risk factor for grade 3 to 4 hematological toxicity after primary chemotherapy(cisplatin(CDDP)/tegafur, gimeracil, oteracil potassium(S1)or CDDP/irinotecan hydrochloride(CPT-11)) in 75 patients with unresectable or recurrent gastric cancer between April 2005 and May 2008. The rate of grade 3 to 4 hematological toxicity was 17.3%(13 patients). Grade 3 to 4 hematological toxicity was the endpoint selected for the analysis. At multivariate analysis, the most important pretreatment risk factors for grade 3 to 4 hematological toxicity in patients receiving primary chemotherapy of unresectable or recurrent gastric cancer were found to be hemoglobin(OR 0.520; p=0.012)and treatment regimen(CDDP/CPT-11)(OR 0.101; p=0.002). Therefore, patients about to receive chemotherapy should be considered in these risk factors.